Smith & Nephew Plc share price today

(SNN)

Smith & Nephew Plc share price is $25.3 & ₹2,143.67 as on 5 Dec 2024, 2.30 'hrs' IST

$25.3

▲

-0.37

(-1.44%)

Market is closed - opens 8 PM, 05 Dec 2024

View live Smith & Nephew Plc share price in Dollar and Rupees. Guide to invest in Smith & Nephew Plc from India. Also see the sentimental analysis on Indian investors investing in Smith & Nephew Plc. Get details on the Indian mutual funds that are investing in Smith & Nephew Plc. Get Analyst recommendations and forecasts along with all the Smith & Nephew Plc's financials.

Smith & Nephew Plc share price movements

$25.28
$25.53
$25.30
0.08%
Downside
Day's Volatility :0.98%
Upside
0.9%
$23.65
$31.72
$25.30
6.52%
Downside
52 Weeks Volatility :25.44%
Upside
20.24%

Smith & Nephew Plc Returns

Period	Smith & Nephew Plc	Sector (Health Care)	Index (Russel 2000)
3 Months	-17.61%	-4.7%	0.0%
6 Months	-2.83%	0.9%	0.0%
1 Year	-0.46%	11.6%	0.0%
3 Years	-22.71%	12.9%	-18.1%

Smith & Nephew Plc Key Statistics

in dollars & INR

Previous Close	$25.67
Open	$25.46
Today's High	$25.53
Today's Low	$25.28
Market Capitalization	$11.2B
Today's Volume	$459.9K
52 Week High	$31.72
52 Week Low	$23.65
Revenue TTM	$5.6B
EBITDA	$1.1B
Earnings Per Share (EPS)	$0.7
PE Ratio	36.83
Dividend Yield	2.91%
Profit Margin	5.41%
Quarterly Earnings Growth YOY	0.24%
Return On Equity TTM	5.84%

How to invest in Smith & Nephew Plc from India?

It is very easy for Indian residents to invest directly in Smith & Nephew Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Smith & Nephew Plc stock in both rupees (INR) and dollars (USD). Search for Smith & Nephew Plc or SNN on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Smith & Nephew Plc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Smith & Nephew Plc shares which would translate to 0.033 fractional shares of Smith & Nephew Plc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Smith & Nephew Plc

11%

Period: Sep 5, 2024 to Dec 4, 2024. Change in 30 Days versus previous period

Search volume for Smith & Nephew Plc on INDmoney from India has grown in the last 30 days as on Dec 5, 2024. 11% more investors are searching Smith & Nephew Plc in the last 30 days versus the previous period.

Global Institutional Holdings in Smith & Nephew Plc

Fiduciary Management, Inc. of Milwaukee
0.97%
Barrow Hanley Mewhinney & Strauss LLC
0.91%
Scharf Investments
0.67%
Goldman Sachs Group Inc
0.56%
Bank of America Corp
0.34%
TPG GP A, LLC
0.34%

Analyst Recommendation on Smith & Nephew Plc

Buy

70%Buy

25%Hold

4%Sell

Based on 24 Wall street analysts offering stock ratings for Smith & Nephew Plc(by analysts ranked 0 to 5 stars)

Based on 24 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Smith & Nephew Plc

What analysts predicted

Upside of 28.67%

Current:

$25.30

Target:

$32.55

Insights on Smith & Nephew Plc

Increasing Revenue
Revenue is up for the last 4 quarters, 1.36B → 2.82B (in $), with an average increase of 17.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 90.27M → 214.0M (in $), with an average increase of 57.8% per quarter
Vs BSX
In the last 1 year, Boston Scientific Corp. has given 64.8% return, outperforming this stock by 64.8%
Vs BSX
In the last 3 years, Boston Scientific Corp. has given 129.2% return, outperforming this stock by 149.9%

Smith & Nephew Plc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$4.9B	↑ 2.92%
Net Income	$663.0M	↓ 13.56%
Net Profit Margin	13.52%	↓ 2.58%

	FY19	Y/Y Change
Revenue	$5.1B	↑ 4.77%
Net Income	$600.0M	↓ 9.5%
Net Profit Margin	11.68%	↓ 1.84%

	FY20	Y/Y Change
Revenue	$4.6B	↓ 11.25%
Net Income	$448.0M	↓ 25.33%
Net Profit Margin	9.82%	↓ 1.86%

	FY21	Y/Y Change
Revenue	$5.2B	↑ 14.3%
Net Income	$524.0M	↑ 16.96%
Net Profit Margin	10.05%	↑ 0.23%

	FY22	Y/Y Change
Revenue	$5.2B	↑ 0.06%
Net Income	$223.0M	↓ 57.44%
Net Profit Margin	4.28%	↓ 5.77%

	FY23	Y/Y Change
Revenue	$5.5B	↑ 6.4%
Net Income	$263.0M	↑ 17.94%
Net Profit Margin	4.74%	↑ 0.46%

	Q3 FY22	Q/Q Change
Revenue	$1.3B	↓ 49.71%
Net Income	$23.0M	↓ 87.01%
Net Profit Margin	1.76%	↓ 5.05%

	Q4 FY22	Q/Q Change
Revenue	$2.7B	↑ 109.79%
Net Income	$48.3M	↑ 109.79%
Net Profit Margin	1.76%	↑ 0.0%

	Q1 FY23	Q/Q Change
Revenue	$1.4B	↓ 50.16%
Net Income	$86.0M	↑ 78.23%
Net Profit Margin	6.29%	↑ 4.53%

	Q2 FY23	Q/Q Change
Revenue	$2.7B	↑ 100.0%
Net Income	$172.0M	↑ 100.0%
Net Profit Margin	6.29%	↑ 0.0%

	Q4 FY23	Q/Q Change
Revenue	$2.8B	↑ 2.14%
Net Income	$90.3M	↓ 47.51%
Net Profit Margin	3.23%	↓ 3.06%

	Q2 FY24	Q/Q Change
Revenue	$2.8B	↑ 1.23%
Net Income	$214.0M	↑ 137.05%
Net Profit Margin	7.57%	↑ 4.34%

	FY18	Y/Y Change
Total Assets	$8.1B	↑ 2.45%
Total Liabilities	$3.2B	↓ 1.15%

	FY19	Y/Y Change
Total Assets	$9.3B	↑ 15.39%
Total Liabilities	$4.2B	↑ 30.55%

	FY20	Y/Y Change
Total Assets	$11.0B	↑ 18.42%
Total Liabilities	$5.7B	↑ 37.88%

	FY21	Y/Y Change
Total Assets	$10.9B	↓ 0.84%
Total Liabilities	$5.4B	↓ 6.65%

	FY22	Y/Y Change
Total Assets	$10.0B	↓ 8.74%
Total Liabilities	$4.7B	↓ 12.05%

	FY23	Y/Y Change
Total Assets	$10.0B	↑ 0.21%
Total Liabilities	$4.8B	↑ 1.34%

	Q3 FY22	Q/Q Change
Total Assets	$10.1B	↑ 0.0%
Total Liabilities	$4.7B	↓ 0.06%

	Q4 FY22	Q/Q Change
Total Assets	$10.0B	↓ 1.38%
Total Liabilities	$4.7B	↑ 0.0%

	Q1 FY23	Q/Q Change
Total Assets	$10.0B	↑ 0.0%
Total Liabilities	$4.6B	↓ 2.04%

	Q2 FY23	Q/Q Change
Total Assets	$9.8B	↓ 1.22%
Total Liabilities	$4.6B	↑ 0.0%

	Q4 FY23	Q/Q Change
Total Assets	$10.0B	↑ 1.45%
Total Liabilities	$4.8B	↑ 3.45%

	Q2 FY24	Q/Q Change
Total Assets	$10.5B	↑ 5.56%
Total Liabilities	$5.3B	↑ 11.89%

	FY18	Y/Y Change
Operating Cash Flow	$931.0M	↓ 14.59%
Investing Cash Flow	$-378.0M	↓ 30.39%
Financing Cash Flow	$-371.0M	↓ 14.52%

	FY19	Y/Y Change
Operating Cash Flow	$1.2B	↑ 25.46%
Investing Cash Flow	$-1.3B	↑ 230.95%
Financing Cash Flow	$7.0M	↓ 101.89%

	FY20	Y/Y Change
Operating Cash Flow	$935.0M	↓ 19.95%
Investing Cash Flow	$-606.0M	↓ 51.56%
Financing Cash Flow	$1.2B	↑ 16528.57%

	FY21	Y/Y Change
Operating Cash Flow	$877.0M	↓ 6.2%
Investing Cash Flow	$-691.0M	↑ 14.03%
Financing Cash Flow	$-645.0M	↓ 155.41%

	FY22	Y/Y Change
Operating Cash Flow	$468.0M	↓ 46.64%
Investing Cash Flow	$-472.0M	↓ 31.69%
Financing Cash Flow	$-926.0M	↑ 43.57%

	Q3 FY22	Q/Q Change
Operating Cash Flow	$130.5M	↓ 36.96%
Investing Cash Flow	$-102.0M	↓ 23.88%
Financing Cash Flow	$-111.0M	↓ 84.23%

	Q4 FY22	Q/Q Change
Operating Cash Flow	$130.5M	↑ 0.0%
Investing Cash Flow	$-472.0M	↑ 362.75%
Financing Cash Flow	$-111.0M	↑ 0.0%

	Q1 FY23	Q/Q Change
Operating Cash Flow	$56.5M	↓ 56.7%
Investing Cash Flow	$-91.0M	↓ 80.72%
Financing Cash Flow	$-43.0M	↓ 61.26%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$56.5M	↑ 0.0%
Investing Cash Flow	$-182.0M	↑ 100.0%
Financing Cash Flow	$-43.0M	↑ 0.0%

Smith & Nephew Plc Technicals Summary

Sell

Neutral

Buy

Smith & Nephew Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Smith & Nephew Plc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Smith & Nephew Plc	0.67%	-2.83%	-0.46%	-22.71%	-41.6%
Stryker Corporation	5.35%	11.44%	35.35%	53.15%	94.43%
Boston Scientific Corp.	5.72%	18.8%	64.96%	122.19%	106.89%
Edwards Lifesciences Corp.	5.76%	-19.56%	1.5%	-37.0%	-9.69%
Abbott Laboratories	-0.78%	12.03%	11.31%	-11.82%	39.28%
Medtronic Plc	-3.5%	5.1%	9.49%	-21.5%	-22.13%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Smith & Nephew Plc	36.83	36.83	0.43	1.41	0.06	0.05	0.03	5.96
Stryker Corporation	42.03	42.03	2.74	12.06	0.19	0.07	0.01	52.86
Boston Scientific Corp.	74.93	74.93	1.64	2.46	0.09	0.05	NA	14.05
Edwards Lifesciences Corp.	27.55	27.55	6.52	2.53	0.19	0.11	NA	16.18
Abbott Laboratories	36.1	36.1	2.31	4.68	0.15	0.06	0.02	22.94
Medtronic Plc	26.38	26.38	1.56	5.2	0.08	0.04	0.03	38.29

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Smith & Nephew Plc	Buy	$11.2B	-41.6%	36.83	5.41%
Stryker Corporation	Buy	$149.5B	94.43%	42.03	16.34%
Boston Scientific Corp.	Buy	$133.7B	106.89%	74.93	11.26%
Edwards Lifesciences Corp.	Buy	$42.5B	-9.69%	27.55	65.86%
Abbott Laboratories	Buy	$206.3B	39.28%	36.1	13.99%
Medtronic Plc	Buy	$110.6B	-22.13%	26.38	12.06%

Smith & Nephew Plc Dividend announcements

Smith & Nephew Plc Dividends December, 2024
In the quarter ending December,2024. Smith & Nephew Plc has declared dividend of $0.29
Read More

About Smith & Nephew Plc

Smith & Nephew plc, also known as Smith+Nephew, is a British multinational medical equipment manufacturing company headquartered in Watford, England.

Organization	Smith & Nephew Plc
Employees	18000
CEO	Dr. Deepak S. Nath Ph.D.
Industry	Health Technology

Management People of Smith & Nephew Plc

Name	Title
Dr. Deepak S. Nath Ph.D.	CEO & Director
Mr. John Terence Rogers	CFO & Executive Director
Mr. Paul Connolly	President of Global Operations
Mr. Andrew Swift	Vice President of Investor Relations
Ms. Helen Barraclough	Group General Counsel & Company Secretary
Ms. Alison Parkes	Chief Compliance Officer & Compliance APAC
Mr. Joe Metzger	Senior Vice President of Marketing Services & Communications
Mr. Philip G. Cowdy	Chief Corporate Development & Corporate Affairs Officer
Ms. Elga Lohler	Chief Human Resources Officer
Dr. Vasant Padmanabhan Ph.D.	President of Research & Development and Ear, Nose & Throat

Important FAQs about investing in Smith & Nephew Plc from India :

What is Smith & Nephew Plc share price today?

Smith & Nephew Plc (SNN) share price today is $25.30.

Can Indians buy Smith & Nephew Plc shares?

Yes, Indians can invest in the Smith & Nephew Plc (SNN) from India.

With INDmoney, you can buy Smith & Nephew Plc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Smith & Nephew Plc at zero transaction cost.

How can I buy Smith & Nephew Plc shares from India?

It is very easy to buy Smith & Nephew Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Smith & Nephew Plc be purchased?

Yes, you can buy fractional shares of Smith & Nephew Plc with INDmoney app.

What are the documents required to start investing in Smith & Nephew Plc stocks?

To start investing in Smith & Nephew Plc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.